Full Text View
Tabular View
No Study Results Posted
Related Studies
Positional Cloning of the Gene(s) Responsible for Alagille Syndrome
This study has been completed.
Study NCT00001642   Information provided by National Institutes of Health Clinical Center (CC)
First Received: April 6, 2000   Last Updated: March 3, 2008   History of Changes

April 6, 2000
March 3, 2008
May 1997
 
 
 
Complete list of historical versions of study NCT00001642 on ClinicalTrials.gov Archive Site
 
 
 
Positional Cloning of the Gene(s) Responsible for Alagille Syndrome
Positional Cloning of the Gene(s) Responsible for Alagille Syndrome

The goal of the project is to identify and clone the gene(s) responsible for the Alagille Syndrome (AGS) by a positional cloning approach. The first step towards this goal is to define the smallest genomic candidate region for AGS at 20p12 and to begin to identify genes within this region which are, by definition, candidate genes for the disease. In a collaborative effort with clinician-investigators studying the Alagille syndrome, metaphase chromosomes and genomic DNA from affected individuals will be studied for subchromosomal deletions and for mutations in the candidate genes. Characterization of genes involved in Alagille syndrome could provide important insight into the pathophysiology of the disease, the development of normal liver and treatment of this disease. Recently, we and others found that mutations in Jagged1, a Notch1 receptor are responsible for Alagille Syndrome.

The goal of the project is to identify and clone the gene(s) responsible for the Alagille Syndrome (AGS) by a positional cloning approach. The first step towards this goal is to define the smallest genomic candidate region for AGS at 20p12 and to begin to identify genes within this region which are, by definition, candidate genes for the disease. In a collaborative effort with clinician-investigators studying the Alagille syndrome, metaphase chromosomes and genomic DNA from affected individuals will be studied for subchromosomal deletions and for mutations in the candidate genes. Characterization of genes involved in Alagille syndrome could provide important insight into the pathophysiology of the disease, the development of normal liver and treatment of this disease.

 
Observational
 
Alagille Syndrome
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
225
March 2000
 

All enrolled affected subjects, whose samples will be analyzed in this study, must meet the criteria for the clinical diagnosis of Alagille Syndrome (Syndromic Bile Duct Paucity) which include liver biopsy findings consistent with Alagille Syndrome and at least 3 of the 5 primary clinical criteria: cholestasis, characteristic face, posterior embryotoxon, "butterfly" vertebrae and cardiac findings.

Both
 
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00001642
 
970122, 97-HG-0122
National Human Genome Research Institute (NHGRI)
 
 
National Institutes of Health Clinical Center (CC)
May 1999

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP